Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX

Biochemical Pharmacology

Volumn 81, Issue 1, 2011, Pages 164-169

  Saxena, Ashima ^a   Sun, Wei ^a   Fedorko, James M ^a   Koplovitz, Irwin ^b   Doctor, Bhupendra P ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Bioscavenger; Guinea pigs; Human serum butyrylcholinesterase; Prophylaxis; Soman; VX

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CARBON DIOXIDE; CHLORIDE; CHOLESTEROL; CHOLINESTERASE; CREATINE KINASE; CREATININE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; NITROGEN; PHOSPHORUS; PROTEIN; SODIUM; SOMAN; TRIACYLGLYCEROL; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CHEMISTRY; CALCIUM BLOOD LEVEL; CARBON DIOXIDE BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHOLINESTERASE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GUINEA PIG; HEMATOLOGY; HISTOPATHOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LD 50; MALE; MEAN RESIDENCE TIME; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTIDOTES; BUTYRYLCHOLINESTERASE; CHEMICAL WARFARE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUINEA PIGS; HALF-LIFE; HUMANS; MALE; ORGANOTHIOPHOSPHORUS COMPOUNDS; SOMAN;

EID: 78549267772     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.09.007     Document Type: Article

References (29)

1. McDonough J.H., Shih T.-M. Atropine and other anticholinergic drugs. Chemical warfare agents: toxicology and treatment 2007, John Wiley & Sons Ltd., West Sussex, England. T.C. Marrs, R.L. Maynard, F.R. Sidell (Eds.).
2. Dirnhuber P., French M.C., Green D.M., Leadbeater L., Stratton J.A. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol 1979, 31:295-299.
3. McLeod C.G.J. Pathology of nerve agents: perspectives on medical management. Fundam Appl Toxicol 1985, 5:S10-S16.
4. Dunn M.A., Sidell F.R. Progress in medical defense against nerve agents. JAMA 1989, 262:649-652.
5. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., Gordon R.K. New approaches to medical protection against chemical warfare nerve agents. Chemical warfare nerve agents: toxicity at low levels 2001, 191-214. CRC Press, Washington, DC. S.M. Somani, J.A. Romano (Eds.).
6. Ashani Y. Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev Res 2000, 50:298-308.
7. Guven M., Sungur M., Eser B., Sari I., Altuntas F. The effects of fresh frozen plasma on cholinesterase levels and outcomes in patients with organophosphate poisoning. J Toxicol 2004, 42:617-623.
8. Stovner J., Stadskleiv K. Suxamethonium apnoea terminated with commercial serumcholinesterase. Acta Anaesth Scand 1976, 20:211-215.
9. Hoffman R.S., Morasco R., Goldfrank L.R. Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol 1996, 34:259-266.
10. Carmona G.N., Schindler C.W., Shoaib M., Jufer R., Cone E.J., Goldberg S.R., et al. Attenuation of cocaine-induced locomotor activity by butyrylcholinesterase. Exp Clin Psychopharmacol 1998, 6:274-279.
11. Duysen E.G., Bartels C.F., Lockridge O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J Pharmacol Exp Ther 2002, 302:751-758.
12. Ashani Y., Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol Sci 2004, 77:358-367.
13. Saxena A., Tipparaju P., Luo C., Doctor B.P. Pilot-scale production of human serum butyrylcholinesterase suitable for use as a bioscavenger against nerve agent toxicity. Process Biochem 2010, 45:1313-1318.
14. Saxena A., Sun W., Luo C., Doctor B.P. Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem-Biol Interact 2005, 157-158:199-203.
15. Clark M.G., Sun W., Myers T.M., Bansal R., Doctor B.P., Saxena A. Effects of physostigmine and human butyrylcholinesterase on acoustic startle reflex and prepulse inhibition in C57BL/6J mice. Pharmacol Biochem Behav 2005, 81:497-505.
16. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
17. Laub P.B., Gallo J.M. NCOMP-a Windows-based computer program for noncompartmental analysis of pharmacokinetic data. J Pharm Sci 1996, 85:393-395.
18. Lenz D.E., Maxwell D.M., Koplovitz I., Clark C.R., Capacio B.R., Cerasoli D.M., et al. Protection against soman or VX poisoning by human butyrylcholinesterase in guinea pigs and cynomolgus monkeys. Chem-Biol Interact 2005, 157-158:205-210.
19. Waner T., Avidar Y., Peh H.-C., Zass R., Bogin E. Hematology and clinical chemistry values of normal and euthymic hairless adult male Dunkin-Hartley guinea pigs (Cavia porcellus). Vet Clin Pathol 1996, 25:61-64.
20. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. In vitro and in vivo quantitative characterization. Biochem Pharmacol 1993, 45:2465-2474.
21. Allon N., Raveh L., Gilat E., Cohen E., Grunwald J., Ashani Y. Prophylaxis against soman inhalation toxicity in guinea pigs by pretreatment alone with human serum butyrylcholinesterase. Toxicol Sci 1998, 43:121-128.
22. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol Appl Pharmacol 1997, 145:43-53.
23. Myers T.M., Sun W., Bansal R., Clark M.G., Saxena A., Doctor B.P. Safety evaluation of human serum butyrylcholinesterase in rhesus monkeys. Proc joint service scientific conf on chem and biol def res 2003.
24. Doctor B.P., Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem-Biol Interact 2005, 157-158:167-171.
25. Ashani Y., Shapira S., Levy D., Wolfe A.D., Doctor B.P., Raveh L. Butyrylcholinesterase and acetylcholinesterase prophylaxis against soman poisoning in mice. Biochem Pharmacol 1991, 41:37-41.
26. Brandeis R., Raveh L., Grunwald J., Cohen E., Ashani Y. Prevention of soman-induced cognitive deficits by pretreatment with human butyrylcholinesterase in rats. Pharmacol Biochem Behav 1993, 46:889-896.
27. Raveh L., Ashani Y., Levy D., De La Hoz D., Wolfe A.D., Doctor B.P. Acetylcholinesterase prophylaxis against organophosphate poisoning. Quantitative correlation between protection and blood-enzyme level in mice. Biochem Pharmacol 1989, 38:529-534.
28. Benschop H.P., Trap H.C., Spruit H.E., Van Der Wiel H.J., Langenberg J.P., De Jong L.P. Low level nose-only exposure to the nerve agent soman: toxicokinetics of soman stereoisomers and cholinesterase inhibition in atropinized guinea pigs. Toxicol Appl Pharmacol 1998, 153:179-185.
29. van der Schans M.J., Lander B.J., van der Wiel H., Langenberg J.P., Benschop H.P. Toxicokinetics of the nerve agent (+/-)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol 2003, 191:48-62.